Loading...
•
Mar 31, 2024
Zura Bio Q1 2024 Earnings Report
Zura Bio reported its financial results for the first quarter of 2024.
Key Takeaways
Zura Bio reported a net loss of $7.7 million for Q1 2024. The company's cash and cash equivalents were $89.8 million as of March 31, 2024, and they raised gross proceeds of approximately $112.5 million in an oversubscribed private placement.
Raised gross proceeds of approximately $112.5 million in an oversubscribed private placement.
Appointed new members to the Executive Management team and Board.
Cash and cash equivalents were $89.8 million as of March 31, 2024.
Net loss for the first quarter of 2024 was $7.7 million.
Forward Guidance
Zura Bio is on track to commence a Phase 2 clinical trial in SSc in the fourth quarter of 2024, followed by a Phase 2 clinical trial in HS in the second quarter of 2025. They are actively monitoring Phase 2 and Phase 3 IL-33 external catalysts in asthma and chronic obstructive pulmonary disease.
Positive Outlook
- On track to commence a Phase 2 clinical trial in SSc in the fourth quarter of 2024.
- Phase 2 clinical trial in HS in the second quarter of 2025.
- Actively monitoring Phase 2 IL-7R external catalysts in ulcerative colitis.
- Actively monitoring Phase 2 IL-7R external catalysts in atopic dermatitis.
- Actively monitoring Phase 2 IL-7R external catalysts in alopecia areata.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...